For Researchers

Coming Soon:

  • Blood Inventory
  • Tissue Inventory

Access to the Penn Medicine BioBank

The Penn Medicine BioBank assists researchers in need of access to human samples. Our facility banks blood specimens (i.e., whole blood, plasma, serum, buffy coat, and DNA isolated from leukocytes) and tissues (i.e.,formalin-fixed paraffin embedded, fresh and flash frozen). All studies requesting specimens must have IRB-approval for access to human samples. Additionally, each study must apply to the Penn Medicine BioBank Steering Committee for approval. Requests for blood and tissue will be reviewed by a panel of scientists and ranked. Priority will be given to those investigators with current NIH funding, but will be made available as recommended by the Steering Committee. These access decisions will be made on an individual basis, though the committee may consider some or all of the following issues: the nature and scope of the project, how much sample is requested, and the impact on Penn Medicine.

Access Process Overview

Requestors must complete the Bio-Bank Access Application in order to utilize this core.

  1. Prior to completing an application, it is recommended that the investigator contact the Penn Medicine Bio-Bank (PMBB) technical director or recruitment supervisor to review sample requirement details and feasibility. The PMBB will assist the investigator in defining their selection criteria and the minimum necessary data elements needed for their study. This step will expedite the process for requesting samples.
  2. After receiving input and guidance from the PMBB staff, investigators should submit an application by email to Kristine Gindele at for distribution to the PMBB Steering Committee. Once received, all proposals will be distributed to the PMBB Steering Committee within 48 business hours.
  3. The committee will consider the impact and feasibility of the proposed study in relation to PMBB resources. Please anticipate a 14 business day evaluation period and plan accordingly. Preferably, the PMBB Steering Committee will review proposals prior to IRB submission.
  4. The PMBB Steering Committee will provide feedback to the investigator with either approval to move forward or with concerns to be addressed. If the PMBB Steering Committee does not approve the application, the investigator will be given the opportunity to respond to the committee's concerns and may re-submit their application.
  5. The PMBB technical director or recruitment supervisor will advise the investigator regarding incorporating PMBB Steering Committee approval into the investigator's IRB submission.
  6. Upon releasing samples and data, researchers will be expected to compensate the PMBB for costs associated with banking, sample pulls, and transportation/shipping expenses.
  7. The PMBB expects that investigators will voluntarily share their analysis results into a communal Penn database in order to build sample characterizations for future studies and to eliminate duplicate analysis on the same sample sets.
  8. If the investigator needs data points in addition to the data points specified in their IRB-approved protocol, the investigator must submit a protocol modification to the IRB and have approval from the IRB before any additional data elements can be utilized.
Institute for Translational Medicine and Therapeutics

3400 Civic Center Boulevard, Building 421
10th Floor, Room 122
Philadelphia, PA 19104-5158